Compare Enact Holdings Inc (ACT) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs ARK Genomic Revolution ETF — how do they compare? Enact Holdings Inc trades at $49.53 (market cap $6.75B), while ARK Genomic Revolution ETF trades at $44.41. The key difference: Enact Holdings Inc pays a 1.95% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ACT | ARKG | |
|---|---|---|
Market Cap | $6.75B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $49.12 | $44.55 |
52-Week Low | $34.93 | $24.02 |
Enterprise Value | $7.05B | — |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $49.47, up 2.0% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong profitability with a net income margin of 54.5% and ROE of 12.9%, supported by recent earnings beats. Revenue growth is modest, and the company maintains a consistent dividend policy. Analyst consensus is a $49.00 price target with a mix of buy and hold ratings.
Outlook is stable with solid fundamentals, but high valuation multiples and overbought technicals suggest limited near-term upside. Risks include reliance on earnings consistency and market sentiment shifts. The stock offers value through dividends and profitability, yet investors should weigh current levels against growth prospects.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
